Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: Specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus

[1]  G. Marek,et al.  LY3 54740: A Systemically Active mGlu2/mGlu3 Receptor Agonist , 2006 .

[2]  D. Schoepp,et al.  Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: Evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo , 2005, Neuropharmacology.

[3]  H. Shannon,et al.  Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing , 2005, Neuropharmacology.

[4]  F. Nicoletti,et al.  Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine‐induced down‐regulation of β‐adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands , 2005, Journal of neurochemistry.

[5]  D. Schoepp,et al.  Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice , 2005, Psychopharmacology.

[6]  C. Swanson,et al.  Metabotropic glutamate receptors as novel targets for anxiety and stress disorders , 2005, Nature Reviews Drug Discovery.

[7]  L. Nisenbaum,et al.  Fast Fos: rapid protocols for single- and double-labeling c-Fos immunohistochemistry in fresh frozen brain sections , 2005, Journal of Neuroscience Methods.

[8]  F. Sharp,et al.  The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis , 2004, Neuropharmacology.

[9]  T. Salt,et al.  Activation of Group II and Group III metabotropic glutamate receptors by endogenous ligand(s) and the modulation of synaptic transmission in the superficial superior colliculus , 2004, Neuropharmacology.

[10]  S. Nakanishi,et al.  Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent , 2004, Neuropharmacology.

[11]  S. Chaki,et al.  Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. , 2004, Biochemical and biophysical research communications.

[12]  J. Rosen,et al.  The neurobiology of conditioned and unconditioned fear: a neurobehavioral system analysis of the amygdala. , 2004, Behavioral and cognitive neuroscience reviews.

[13]  S. Nakanishi,et al.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity , 2004, Neuropharmacology.

[14]  D. Schoepp,et al.  Anxiolytic Activity of the MGLU2/3 Receptor Agonist LY354740 on the Elevated Plus Maze is Associated with the Suppression of Stress-Induced c-Fos in the Hippocampus and Increases in c-Fos Induction in Several Other Stress-Sensitive Brain Regions , 2004, Neuropsychopharmacology.

[15]  R. Hen,et al.  Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants , 2003, Science.

[16]  M. Bergeron,et al.  Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus , 2003, Neuropharmacology.

[17]  B. Cohen,et al.  Cells in midline thalamus, central amygdala, and nucleus accumbens responding specifically to antipsychotic drugs , 2003, Psychopharmacology.

[18]  C. Grillon,et al.  Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans , 2003, Psychopharmacology.

[19]  L. Levine,et al.  LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress , 2003, Stress.

[20]  Michael Davis,et al.  Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. , 2002, Behavioral neuroscience.

[21]  J. Kemp,et al.  Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -/- mice , 2002, Neuropharmacology.

[22]  G. Marek,et al.  Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? , 2002, Current drug targets. CNS and neurological disorders.

[23]  T. Salt,et al.  Metabotropic glutamate (mGlu) receptors and nociceptive processing , 2001 .

[24]  D. Schoepp.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. , 2001, The Journal of pharmacology and experimental therapeutics.

[25]  Andrzej Pilc,et al.  The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration , 2001, Psychopharmacology.

[26]  R. Shigemoto,et al.  Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites , 2001, Neuroscience.

[27]  F. Nicoletti,et al.  Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  P. Ornstein,et al.  [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. , 2001, The Journal of pharmacology and experimental therapeutics.

[29]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[30]  B. Meldrum,et al.  Anti-epileptic activity of group II metabotropic glutamate receptor agonists (−)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) and (−)-2-thia-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY389795) , 2001, Neuropharmacology.

[31]  R. Anwyl,et al.  Presynaptic group II mGluR inhibition of short-term depression in the medial perforant path of the dentate gyrus in vitro. , 2001, Journal of neurophysiology.

[32]  D. Schoepp,et al.  Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors , 2000, Journal of neurochemistry.

[33]  P. Shinnick‐Gallagher,et al.  Cocaine and kindling alter the sensitivity of group II and III metabotropic glutamate receptors in the central amygdala. , 2000, Journal of neurophysiology.

[34]  W. Spooren,et al.  Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. , 2000, European journal of pharmacology.

[35]  C. Nemeroff,et al.  Chronic Administration of the Triazolobenzodiazepine Alprazolam Produces Opposite Effects on Corticotropin-Releasing Factor and Urocortin Neuronal Systems , 2000, The Journal of Neuroscience.

[36]  D. Jane,et al.  Pharmacological agents acting at subtypes of metabotropic glutamate receptors , 1999, Neuropharmacology.

[37]  H. Wässle,et al.  Modulation of the intracellular calcium concentration in photoreceptor terminals by a presynaptic metabotropic glutamate receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Hitzemann,et al.  Chlordiazepoxide-induced expression of c-Fos in the central extended amygdala and other brain regions of the C57BL/6J and DBA/2J inbred mouse strains: relationships to mechanisms of ethanol action. , 1999, Alcoholism, clinical and experimental research.

[39]  R. Anwyl.  Metabotropic glutamate receptors: electrophysiological properties and role in plasticity , 1999, Brain Research Reviews.

[40]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[41]  F. Bloom,et al.  Acute ethanol induces c-fos immunoreactivity in GABAergic neurons of the central nucleus of the amygdala 1 Published on the World Wide Web on 27 May 1998. 1 , 1998, Brain Research.

[42]  A. Arimura,et al.  Distribution of urocortin‐like immunoreactivity in the central nervous system of the rat , 1998, The Journal of comparative neurology.

[43]  N. Mizuno,et al.  Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody , 1998, Neuroscience Research.

[44]  P. Ornstein,et al.  LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors , 1998, Neuropharmacology.

[45]  Ayae Kinoshita,et al.  Differential Presynaptic Localization of Metabotropic Glutamate Receptor Subtypes in the Rat Hippocampus , 1997, The Journal of Neuroscience.

[46]  D. Schoepp,et al.  Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. , 1997, Journal of medicinal chemistry.

[47]  Paul Antoine Salin,et al.  Use-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors , 1997, Nature.

[48]  S. Nakanishi,et al.  Impairment of Hippocampal Mossy Fiber LTD in Mice Lacking mGluR2 , 1996, Science.

[49]  David Lovejoy,et al.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor , 1995, Nature.

[50]  C H Beck,et al.  Conditioned fear-induced changes in behavior and in the expression of the immediate early gene c-fos: with and without diazepam pretreatment , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[51]  S. Nakanishi,et al.  Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat , 1993, Neuroscience.

[52]  A. L. Humphrey,et al.  cFos labeling in rat superior colliculus: Activation by normal retinal pathways and pathways from intracranial retinal transplants , 1992, Experimental Neurology.

[53]  J. Criado,et al.  ORIGINAL RESEARCH ARTICLE Differential sensitivity of c-Fos expression in hippocampus and other brain regions to moderate and low doses of alcohol , 1997 .

[54]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.